Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 13 Results

Title
Intervention Indication Therapeutic Area Year Actions
Avelumab for gastric and gastroesophageal junction adenocarcinoma – third line Avelumab (Bavencio; MSB-0010718C) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Avelumab for gastric or gastro-oesophageal junction cancer - first line maintenance Avelumab (Bavencio; MSB-0010718C) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Nivolumab for oesophageal or gastro-oesophageal junction cancer - adjuvant Nivolumab (Opdivo; BMS-936558; ONO-4538) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2019 View  |  Download
Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Pembrolizumab (KEYTRUDA) for advanced, metastatic oesophageal cancer – second line Pembrolizumab (Keytruda; MK-3475) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2017 View  |  Download
Pembrolizumab in addition to chemotherapy for perioperative treatment of gastric or gastro-oesophageal junction adenocarcinoma FLOT , Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Pembrolizumab in addition to trastuzumab and chemotherapy for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma – First-line Pembrolizumab (Keytruda; MK-3475) , Trastuzumab (Herceptin; RG-597) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Pembrolizumab plus chemotherapy for the treatment of gastric cancer or gastro-oesophageal junction cancer – First Line Pembrolizumab (Keytruda; MK-3475) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2021 View  |  Download
Ramucirumab (Cyramza) + capecitabine or 5-FU + cisplatin for gastric cancer of GOJ – treatment naive for palliative chemotherapy 5-Fluorouracil , Capecitabine (Xeloda) , Cisplatin (Platinol) , Ramucirumab (Cyramza) Gastro-oesophageal junction cancer Gastrointestinal Cancer 2017 View  |  Download
Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer - after two or more therapies Rivoceranib (Apatinib; YN968D1) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2020 View  |  Download
1 2
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications